Show simple item record

dc.contributor.authorSchaan, Beatriz D'Agordpt_BR
dc.contributor.authorScheffel, Rafael Selbachpt_BR
dc.date.accessioned2020-12-24T04:20:42Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn1758-5996pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/216842pt_BR
dc.description.abstractThere is a clinical imperative to improve metabolic control in the treatment of patients with type 1 diabetes, but in doing so, hypoglycemia should be avoided at all costs. Insulin analogues and the assumption they would better mimic the pharmacokinetic profile of endogenous insulin secretion emerged as a magic bullet in the treatment of patients with type 1 diabetes. However, although insulin analogues have pharmaceutical properties, such as pharmacodynamic stability, reproducibility of action, and a more physiological timing of action, which could possibly facilitate insulin use, the results obtained in clinical practice have not been as good as expected. Like all clinical decisions, the decision regarding which insulin would be better for the patient should be, if possible, evidence based. Here, we briefly discuss evidence for the use of insulin analogues and the different views with respect to the available evidence that lead to different interpretations and decisions regarding the use of this new technology.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofDiabetology and Metabolic Syndrome. São Paulo. Vol. 7:35 (2015), 4 p.pt_BR
dc.rightsOpen Accessen
dc.subjectDiabetes mellitus tipo 1pt_BR
dc.subjectInsulinapt_BR
dc.titleModern insulins, old paradigms and pragmatism : choosing wisely when deciding how to treat type 1 diabetespt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000990088pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record